Golden Goose Awards: Your tax dollars at work for science research

By Karen KaplanLos Angeles TimesSeptember 13, 2012, 12:32 p.m.

The National Institutes of Health are on track to receive more than $30 billion in federal funding in next year’s budget, andNASA is set to receive at least $17 billion. On top of that, Congress looks likely to dole out more than $7 billion to the National Science Foundation; nearly $5 billion to the Department of Energy’s Office of Science; and several billion more to other federal agencies like the National Oceanic and Atmospheric Administration, the U.S. Geological Survey, theU.S. Department of Agriculture’s Agricultural Research Service and the Defense Advanced Research Projects Agency.

It’s not always clear what that money is going to buy, and some critics say say it should be dialed back. Most famously, former Sen. William Proxmire (D-Wisc.) established the Golden Fleece Awards to “honor” what he saw as wasteful public spending. Winners included the National Institute onAlcohol Abuse and Alcoholism (for studying whether fish drunk on tequila are more aggressive than sober fish) and the Office of Education (for spending nearly $220,000 to create a course to teach college students how to watch TV), according to this report from the Milwaukee Journal Sentinel.

Now another member of Congress, Rep. Jim Cooper (D-Tenn.), brings us the antidote to the Golden Fleece Awards — the Golden Goose Awards, which honor scientists “whose seemingly odd or obscure federally funded research turned out to have a significant impact on society.”

The winners of the inaugural Golden Goose Awards are:

–Physicist Charles Townes, whose research enabled the invention of lasers, though no one realized that when he was working in the 1950s. He won a Nobel Prize in Physics for this work back in 1964.

–Eugene White, Rodney White, Dellay Roy and Jon Weber, who discovered a widely used bone graft material by studying tropical coral in the 1960s.

–Martin Chalfie, Roger Tsien and Osamu Shimomura, whose studies of glowing jellyfish led to “numerous medical research advances and to methods used widely by the pharmaceutical and biotechnology industries,” according to this press release. Members of this team also won a Nobel Prize – this time for chemistry – in 2008.

More information about the scientists and their serendipitous discoveries is online atwww.goldengooseaward.org.

The awards will be presented at a Capitol Hill ceremony involving members of Congress from both major parties. The awards are also backed by a dozen organizations: The American Assn. for the Advancement of Science; the Assn. of American Universities; the Assn. of Public and Land-Grant Universities; the Breakthrough Institute; the Progressive Policy Institute; the Richard Lounsbery Foundation; the Science Coalition; the Task Force on American Innovation; United for Medical Research; the Assn. of American Medical Colleges; the American Chemical Society; and the American Mathematical Society.

You can check out details on federal funding for science at this helpful ScienceInsider page, from the folks at the American Assn. for the Advancement of Science.

Apple’s iPhone 5 puts Europe in 4G slow lane

By Paul Sandle and Leila Abboud

LONDON/PARIS | Fri Sep 14, 2012 8:23am EDT

(Reuters) – Apple’s iPhone 5, launched to great fanfare in the United States on Wednesday, will not work on superfast mobile broadband networks in much of Europe, potentially confusing consumers and setting back the development of 4G services in the region.

The problem lies in the range of spectrum – the airwaves used to carry mobile signals – used in Europe. The iPhone 5 is not compatible with 4G services on the 800MHz and 2.6GHz bands deployed across much of western Europe, including Spain, Italy and France. Instead, it works on the 1.8GHz band, which is still being used for voice calls by most operators in Europe.

Apple will produce three models of the iPhone: one optimized for U.S. carrier AT&T’s network and spectrum bands, another for Sprint and Verizon’s U.S. norms and a third for the rest of the world, including two European operators.

Only Deutsche Telekom in Germany and Everything Everywhere in the UK will initially be able to offer the fastest internet access to iPhone 5 users in their markets, because they are the carriers holding the right frequencies.

Apple could later introduce other models compatible with more European operators’ needs, analysts say, but for now some European operators will be hamstrung.

Vodafone and Telefonica’s 02 look to be at a disadvantage in the UK and Germany, two of Europe’s biggest mobile markets, because the iPhone won’t run on their 4G gear.

“Telecoms executives in Europe had a big dream that the iPhone would be the accelerator to kickstart 4G demand in their markets,” Informa analyst Thomas Wehmeier said. “That dream has now gone up in smoke because Apple has made the U.S. and Asia norms the priority and short-changed Europe.”

Europe’s construction of 4G networks is lagging behind the U.S. and Asia, though European operators are expected to spend $15.25 billion over the next three years to upgrade infrastructure to 4G speeds, according to Rethink Technology Research.

The region has only a few hundred thousand 4G subscribers, most of whom use laptop dongles or home routers because there are few compatible smartphones available.

That is starting to change as Samsung, Nokia and HTC bring out 4G-compatible smartphones that work on European norms. The lack of a compatible iPhone, however, is sure to disappoint some operators hoping to benefit from the positive marketing buzz around Apple’s latest device.

It remains to be seen how much a lack of 4G speeds will hamper sales of the iPhone 5 in Europe. Apple doesn’t break down regional revenue, but market research group Canalys says that 22 percent of iPhones sold in the second quarter were in Europe.

Consumers don’t necessarily understand the thorny details of mobile broadband speeds, and operators don’t make things simpler with advertising that often refers to souped-up 3G technologies – which boost speeds via a software upgrade – as offering 4G speeds.

A survey from consultancy Analysys Mason showed that 46 percent of iPhone 4 users believe that they already have 4G capability, even though they don’t.

Analyst Matthew Howett at the consultancy Ovum said that 4G capability was the iPhone 5’s biggest selling point.

“Outside the hardcore loyal Apple fans, who will buy it anyway, the next biggest attraction of the device is its 4G capability,” he said.

“For those markets where it can be used on a 4G network, I think it’s going to do particularly well, and obviously one of those is the UK. So for Everything Everywhere, this is set to be a real winner.”

Even without 4G, the new iPhone will support the faster version of 3G, known as DC-HSDPA, with up to 42 megabit speeds – faster than many home Internet connections. Long-term evolution (LTE) technology, as the true 4G gear is dubbed, can offer up to 100 megabit speeds.

O2 Chief Executive Ronan Dunne said the iPhone 5 would remain popular on its network in Britain despite the lack of 4G. “The new device will work brilliantly on our network,” he said in an interview.

Hutchison’s 3 brand, Britain’s smallest operator, is in line to buy surplus spectrum from Everything Everywhere in the iPhone-compatible band, so it may eventually offer a faster service.

A spokesman for France Telecom also talked up the better speeds that customers of its Orange mobile brand would receive on the new iPhone in France and Spain, despite not having 4G.

However, operators have to be careful about how they advertise fast mobile broadband speeds on the iPhone to avoid breaking Apple’s strict rules on marketing, Ovum analyst Howett said.

Apple was fined roughly $2.3 million by an Australian court in June for misleading advertising of the iPad, which it said was 4G-compatible when it was not.

The iPhone 5 will go on sale in the United States, Britain, France, Germany, Australia, Canada, Hong Kong, Japan and Singapore on September 21, with pre-orders a week earlier. A further 22 countries, including 21 in Europe, will launch on September 28.

(Additional reporting by Tarmo Virki in Helsinki and Sinead Carew in New York; Editing by David Holmes and David Goodman)

New Breed of Robotics Aims to Help People Walk Again

Published: September 11, 2012

RICHMOND, Calif. — When Joey Abicca pokes a metal crutch into the ground with his right arm, tiny motors start whirling around his left leg, lifting it and moving it forward. When he does the same with his left arm, the motors whir to life again and his right leg takes a step. The metallic whine is like something out of the movie “RoboCop.”

Robotic legs are controlled by a computer on the user’s back.

Mr. Abicca, a 17-year-old from San Diego, is essentially wearing a robot. His bionic suit consists of a pair of mechanical braces wrapped around his legs and electric muscles that do much of the work of walking. It is controlled by a computer on his back and a pair of crutches held in his arms that look like futuristic ski poles.

Since an accident involving earth-moving equipment three years ago that damaged his spinal cord, Mr. Abicca has been unable to walk on his own. The suit, made by a company called Ekso Bionics, is an effort to change that.

“It’s awesome — I love getting back up,” Mr. Abicca said before strapping on the legs during his recent visit to the company’s headquarters here. “Even just standing up straight is awesome.”

Ekso is one of several companies and research labs that are working on wearable robots made to help disabled people or to make the human body superhuman. In 2010, Raytheon released a suit for soldiers that is designed to reduce injuries from heavy lifting. And in Israel, a company called Argo Medical Technologies also makes a robotic suit to help paraplegics walk again.

Ekso says it was the first company to introduce a self-contained robotic suit, without any tethers to, say, a power supply. And though its suits for the disabled are now used only in rehabilitation centers, it is looking ahead to a day when they will let people take to the sidewalks, the shopping malls — and maybe even the woods.

Ekso, which was founded seven years ago by engineers in Berkeley, Calif., takes its name from the word exoskeleton, meaning a skeleton that is on the outside of the body. Originally financed by the military, the company collaborated with the University of California, Berkeley, and the military contractor Lockheed Martin on a device called the Hulc, which allows soldiers to carry up to 200 pounds of equipment over mixed terrain.

In February, Ekso started shipping exoskeletons that are being used in physical therapy to get people out of wheelchairs and using their lower bodies so their muscles do not deteriorate. About 15 rehabilitation centers in the United States are using the suits; they pay $140,000 for each one, along with a $10,000 annual service contract.

With a frame of aluminum and titanium, the bionic suit, called the Ekso, is battery-powered and weighs about 50 pounds. The suit is not yet at the point where a disabled person can use it independently. The batteries last three hours, at which point a physical therapist needs to replace them. Supervision also ensures that a patient does not fall over; the company said hundreds of people have walked in the suit, and none had fallen.

The Ekso suit is already going beyond just helping people walk again. The latest version released last month includes walking modes with different difficulty levels to challenge patients to make progress in their rehabilitation.

In the first mode, when a patient is first learning to walk with the suit, a physical therapist sets the step length and speed and presses a button on a computer to trigger each step. In the second mode, the patient can trigger a step with buttons on the crutches. And in the third, most advanced mode, once the patient has learned to maintain her balance in the suit, she can trigger the suit to take a step just by shifting her weight.

Patients learn to walk in the robotic suits surprisingly quickly, said Eythor Bender, chief executive of Ekso Bionics, who previously worked at Ossur, a company that made artificial limbs. “People who come in haven’t walked for years and years,” he said in an interview. “They are walking on their own in two days.”

Yoky Matsuoka, the former head of innovation at Google and now vice president for technology at Nest, which makes a smart thermostat, said the time was right for exoskeletons to graduate from science-fiction fantasy to commercial reality. Battery technology has improved significantly, materials like plastics and carbon fibers have gotten more lightweight and durable, and robotic systems have become easier to control, she said.

“In the last 10 years, the evolution of some of those materials and some technologies allows us to make robots that really stay human-safe and human-friendly,” Ms. Matsuoka said.

However, the cost of such devices for medical use could still be an obstacle, she said, because such specialized equipment sells in smaller quantities, making it difficult to bring the price down. She said that wider use by the military could help.

At some point, the Ekso suit may have to clear some regulatory hurdles. The current version of the suit is exempt from regulation, but if the company introduced one for personal use at home, it would probably have to gain approval from the Food and Drug Administration, said John Tugwell, director of regulatory affairs at Ekso.

Ekso is hoping that the suits will, in the next few years, really start to go places.

Russ Angold, a founder and the chief technology officer of the company, predicted that exoskeletons, like today’s smartphones, would slim down and get more powerful and affordable, becoming part of everyday life.

“The dream at the end of the day is be able to walk into a sporting goods store, like an REI, and pick up an exoskeleton,” Mr. Angold said. “They’re like the jeans of the future.”

Super stretchy gel doesn’t crack under pressure, self-heals too

By Amina KhanLos Angeles TimesSeptember 10, 2012, 3:14 p.m.

Imagine a substance made of about 90% water that is resilient, compatible with living tissue and can stretch to more than 20 times its own length without breaking.

A team of American and Korean researchers have managed to make just such a material by combining two unremarkable gels — creating a supergel with strengths derived from both.

Though it’s meant to be a proof of concept, gels that are similarly tough and stretchy could one day be used to make replacements for cartilage and other biological tissues, which must be flexible enough to work inside a living body while also strong enough to bear the forces exerted on it.

The gels being studied consist of chains of linked polymers that float in water, their primary ingredient. The result is a hydrogel with a unique set of characteristics. The gels have a range of uses, including tissue engineering and drug delivery. The tougher variety of these gels is used to make contact lenses.

But the particular hydrogel made by the American and Korean team has a stretchiness that puts it in a class by itself. It was described this week in the journal Nature.

“It’s the toughest hydrogel ever reported, we believe,” said Zhigang Suo, a mechanical engineer at Harvard University and senior author of the paper. “So far, nobody has challenged this claim.”

Many gels are brittle — they break easily. Engineers have gotten around that problem by combining different types of gels whose structures work together to effectively dissipate energy for maximum toughness.

Most of these combinations consist of two types of gels — a relatively strong and stiff one with a dense network of chemically-bonded polymers and another one whose polymer network is more loosely packed. That way, when a crack propagates through a stiff gel and breaks its chemical bonds along the way, the looseness of the second gel helps dissipate the energy and reduce the breakage.

But some breakage is inevitable, and it’s hard to repair. The result is a gel that’s weakened and becomes fatigued quickly after repeated compressions.

Suo’s team solved this problem by including in the mix a second gel whose chains of polymers were linked by calcium ions. These ionic bonds are weaker than covalent bonds. But unlike covalent bonds, they can re-form very easily. So when a crack seems to be imminent, the calcium ions break off and “unzip” the polymer chains, dissipating some of the energy. By taking that hit, the covalent bonds in the dense gel can remain intact.

Later, when the stress subsides, the calcium ions can return back to their initial positions, “re-zipping” the ionic bonds back together.

This new hydrogel has been stretched up to 21 times its original length. (For the sake of comparison, a typical rubber band can stretch about six times its resting length.) It can withstand mechanical stresses of up to 9,000 joules per square meter of fracture energy — nine times better than cartilage, and about as good as natural rubber.

This type of gel could be a boon for patients suffering a range of conditions, Kenneth Shull, a materials scientist at Northwestern University, wrote in a commentary on the paper. Perhaps artificial kneecaps and better scaffolds for growing organs might be around the corner.

Small business confidence rises in August

WASHINGTON | Tue Sep 11, 2012 8:02am EDT

(Reuters) – Small business sentiment rose in August for the first time in four months as more owners anticipated better business conditions after the November 6 elections and increased sales.

The National Federation of Independent Business said on Tuesday its optimism index rose 1.7 points to 92.9 last month.

While owners expected an improvement in business conditions over the next six months, they still did not believe that this was a good time to expand operations.

“But looking past the election and year end, owners became a bit more optimistic about improvements in real sales volumes and business conditions,” the NFIB said in a statement.

There were gains in spending and hiring measures last month, with job creation plans doubling. The number of owners reporting job openings were hard to fill increased modestly.

Plans for capital outlays rose, but businesses continued to keep their inventories lean. The share of owners anticipating a rise in inflation-adjusted sales rose last month, snapping a five-month decline.

(Reporting By Lucia Mutikani; Editing by Andrea Ricci)

Investors cash-in on land deals as U.S. housing picks up

By Katya Wachtel

NEW YORK | Mon Sep 10, 2012 1:16am EDT

(Reuters) – From the outskirts of Las Vegas to the coast of California, stretches of undeveloped land in some of the most depressed housing markets in the U.S. are in high demand.

Money managers such as BlackRock Inc, hedge fund Angelo Gordon & Co and real estate investment firm Starwood Capital, are beginning to cash-in on so-called shovel-ready residential land-tracts with most of the pre-construction and zoning approvals already in place.

The investors snapped up land on the cheap in bankruptcy proceedings, from cash-strapped home developers and banks that seized the properties after foreclosing on them when builders ran out of money.

Now they are re-selling the land, often for returns of more than 20 percent on their initial investment, in the latest sign of a modest recovery in the U.S. housing market. Other investors, meanwhile, are looking to partner with homebuilders to develop the tracts.

Some, like Paulson & Co, which has also been active in the space, will hold onto the land for sometime before re-selling it to buyers.

“We are coming out of the mother of all housing cycles, and residential land is the best way to play the ultimate recovery,” said Michael Barr, a Paulson & Co portfolio manager, who oversees the Paulson Real Estate Recovery fund, which has under $500 million in assets for the $19.5 billion hedge fund. “Land is the highest returning component of the home building equation.”

Single-family home sales in the U.S. rose 3.6 percent in July, matching a two-year high achieved in April. In July, applications for building permits hit the highest level since August 2008.

Foreclosures are also slowing in many regions. And, the market for existing single-family home rentals has gotten so hot that institutional investors are racing to raise money to buy foreclosed homes from the nation’s banks and then rent them out.

But shovel-ready land is a potentially more lucrative way to bet on a housing recovery – though investors may require a good deal of patience because it could take several years for developers to build new homes in some of the areas hit hardest during the financial crisis.

“These returns are back-end loaded, and more of an opportunistic, higher risk strategy,” said Dale Gruen, a senior portfolio manager for BlackRock Real Estate, which has raised a fund that invests in such lots. “Single family rental is one in which returns are a more moderate.”

Land that already has all the planning permissions required to begin construction is seen as a better bet than sites without all the boxes ticked because the process of gaining those approvals from local, state and federal agencies can take years, and is also a costly procedure.

Investors and real estate analysts do caution that a full-blown housing recovery is still some time off.

“The housing market is getting better but we’re not quite there yet,” said Stephen Malpezzi, an economist at housing data company Zillow and a professor at the University of Wisconsin’s Department of Real Estate and Urban Land Economics. “We all get excited when we see a few months of positive numbers, but we are still in the middle” of a fragile period for the housing sector, he said.

Still, Paulson’s Barr says it is only a matter of time before the market fully ripens. “We think there is going to be a land shortage coming out of the downturn.”

The Paulson real estate fund, which launched in 2010 and required investors to lock-up their money for 10 years, currently owns about 25,000 home sites in Florida, Arizona, Nevada, Colorado and California, all of which were acquired through some form of distressed sale.

Recently, Paulson, whose flagship fund has struggled mightily in the past two years, scooped up 875 acres of land in a resort development called Lake Las Vegas in Henderson, Nevada, for $17 million. Located about 30 miles from Las Vegas, the resort developer filed for bankruptcy in 2008. The acquisition adds about 3,500 home sites to Paulson’s real estate portfolio.

DIRT-CHEAP DIRT

The Paulson fund, whose founder John Paulson rose to fame and fortune by betting on the collapse of the subprime mortgage market, got into this market in 2010. Hillwood Development and Starwood got into the market even earlier. But new entrants are joining the hunt all the time given the ability to still buy land with development approval for as little as 30 cents on the dollar.

For instance, McRae Group of Companies, a Scottsdale Arizona-based real estate firm is pitching potential investors on a fund that will invest in such land projects in the Phoenix metro area, according to a marketing brochure.

BlackRock, which manages $3.56 trillion in assets, raised $120 million for a fund that invests in shovel-ready properties, buying up land in the San Francisco area, Orange County, Calif., West Palm Beach, Fla. and northern Virginia.

The fund, which finished making investments in June, is now in the process of selling assets back to homebuilders. A person familiar with the fund said the typical return on these types of properties ranges from 20 percent to 35 percent, depending on the strategy and market. Blackrock’s Gruen declined to comment on future investments, but a person familiar with the situation said the firm is considering raising money for a new fund.

There is a rebound in the market for shovel-ready land in the Las Vegas region, said Laus Abdo, executive director of Las Vegas-based TriArchic Advisors, a real estate investment and advisory firm. “Prices have gone from $20,000 a finished lot 18 months ago, to $30,000 – $45,000 per lot today in places like Las Vegas,” Abdo said.

Ross Perot Jr’s Dallas-based investment firm, Hillwood Development, is one early buyer of land now cashing in on its bet thanks to signs of a revival in housing markets in Nevada, California, Texas and Florida. During the recession, Hillwood bought shovel-ready land from cash strapped home builders.

In one instance, the firm purchased a portfolio of 8,700 undeveloped home lots in 2008, which has on average tripled in value.

Fred Balda, the president of Hillwood Communities, said its assets in Las Vegas have proven to be particularly profitable.

Balda said that the strategy overall has been “extremely successful”, but some portfolios, such as those containing land in Reno, Nevada, are still struggling, highlighting the local nature of the U.S. housing market and the uneven nature of the recovery.

Still, many national home builders are flexing their muscles again. Jeffrey Metzger, CEO of KB Home, said in June that the company is “aggressively reinvesting in new land assets and communities.” Similarly, Lennar said it spent $287 million on land and land development in the second quarter, up 74 percent from a year earlier.

The proof of that new building activity can be seen on the ground in places like Las Vegas as well.

Earlier this year, driving through new residential real estate developments in North-West Las Vegas in May, TriArchic’s Abdo pointed to rows of shiny new signs of all the major U.S. homebuilders, from Lennar to Beazer Homes and DR Horton. It’s evidence, he said, of a housing recovery starting to get its legs.

“The engine is cranking back up here in Vegas,” Abdo said.

(Reporting By Katya Wachtel; editing by Matthew Goldstein, Jennifer Ablan, Martin Howell and Bernard Orr)

With Gulf oil deal, PXP jumps into energy big leagues

By Ernest Scheyder

Mon Sep 10, 2012 11:31am EDT

(Reuters) – Plains Exploration & Production Co (PXP.N) is paying $5.55 billion for BP Plc’s (BP.L) stake in some deepwater Gulf of Mexico wells, a deal that boosts its power in the North American energy market and sharpens its focus on crude oil.

Shares of Plains, commonly known by the stock exchange symbol “PXP,” fell more than 8 percent, however, as investors were wary about the price of the deal and the $7 billion in debt that will fund it.

By buying such a large network of oil exploration rigs, Plains Exploration is effectively jumping into the energy industry big leagues with Anadarko Petroleum Corp (APC.N), Devon Energy Corp (DVN.N) and other large independent oil and natural gas producers.

The company was spun off from privately held Plains Resources Inc in 2002 and had previously focused much of its attention on oil drilling in Southern California.

Roughly two-thirds of PXP’s operations will now be in the Gulf, with one-third on land, and daily production will triple to 300,000 barrels of oil equivalent per day. The deal is part of the company’s strategy to focus less on natural gas, whose prices are at a decade low, and more on lucrative crude oil.

“This is not your brother’s Gulf of Mexico,” PXP Chief Executive James Flores told investors on a conference call. “This has very long life and we have a well-developed plan for the next eight years.”

The move helps BP shed smaller, older assets to focus on larger, newer wells that are more lucrative. It also helps the company reach its goal of raising $38 billion from asset sales to pay for damages from the massive 2010 oil spill in the Gulf of Mexico.

Eleven people died and 4.9 million barrels of oil spewed from the mile-deep (1.6 km-deep) Macondo oil well in by far the worst offshore U.S. oil spill.

DEBT LOAD

The deal pushes PXP’s debt load above the company’s roughly $5 billion market cap. Executives tried to assuage investors by outlining a plan to use cash flow in 2013 and 2014 to retire its borrowings.

The company will hold some of the $7 billion in debt as cash and is not issuing new stock.

PXP shares were down 8.1 percent at $37.06 on Monday morning on the New York Stock Exchange. In London, BP shares were up 0.9 percent at 438.8 pence.

The final price tag was “significantly higher than we expected,” RBC Capital Markets wrote in a research note. Last month the brokerage had estimated the assets to be worth about $2.2 billion.

TPH Energy Research said the deal was good news for BP as it looks to move beyond the 2010 oil spill.

“A reduced and more-focused exposure to the Gulf of Mexico is welcome for BP, we think, in the midst of recently escalated” legal action by the U.S. government against the company for the spill, TPH said in a research note.

The properties that Houston-based PXP is acquiring were producing an estimated 59,500 barrels of oil equivalent net per day at the end of July.

PXP is buying London-based BP’s 100 percent stake in the Marlin, Dorado, and King and Horn Mountain fields. It said it would also pay $560 million to acquire the remaining 50 percent working interest in the Holstein Field from Royal Dutch Shell Plc (RDSa.L).

PXP will also get BP’s 33.33 percent working interest in the Diana-Hoover Field, which is operated by ExxonMobil Corp (XOM.N), and BP’s 31 percent stake in the Ram Powell field, which is operated by Shell Offshore Inc.

The platforms at the wells are roughly 10 years old and have successfully weathered several storms, Flores said.

PXP plans to hedge up to 90 percent of oil production through 2015 to lock in current prices and guard against a drop from current levels of around $100 per barrel, executives said.

The company, which sold natural gas assets in Texas for $785 million last November, said it expected the BP deal to close by the end of the year.

A source told Reuters on Sunday that BP was in talks to sell some of its Gulf of Mexico oil fields to PXP.

(Reporting by Ernest Scheyder in New York and Swetha Gopinath in Bangalore; Editing by Sriraj Kalluvila, Lisa Von Ahn and Matthew Lewis)

Experienced investors can stabilize markets

By CHARLES E. CARRIER

As the economy continues to move forward, slowly and erratically, there are considerable opportunities involving the purchase and sale of distressed homes. These circumstances vary significantly across the country, which is why it is useful to understand the profile of the markets and the investors who operate in each city.

Dallas-Fort Worth represents a classic “investor” market, as opposed to a “speculator” market. The characteristics of the former, which are relevant for reviewing the real estate market in any given area, include: income and rental rates that align with property values; a moderate level of new residential construction, even during the real estate boom; a large, diverse and stable economy; and solid population growth and demographic trends.

Based on these criteria, a real estate agent or broker should be able to work with a core group of long-term, seasoned, local investors who act as a stabilizing force on the market.

In fact, many of the problems responsible for the collapse of the real estate market elsewhere — rampant speculation, easy access to credit, lack of financial oversight and a boom-to-bust mentality — are not as prevalent in the Dallas-Fort Worth area. Apply these factors to other cities, and you will quickly know the relative health of the real estate market in your city.

For sellers, this means that realistic exit strategies from otherwise tough situations continue to exist. For neighboring homeowners, this improves the likelihood of price recovery — thanks in part to the liquidity and property improvement enabled by the financial community.

Compare this approach to the dynamics in Southern California or Las Vegas. Rapidly increasing prices bring speculators and even less scrupulous actors to a market where the situation devolves into “buy/fix/flip.” The mentality is to get in and out quickly, before the bubble bursts.

As prices rise, there are no cash flow investors — rental rates are inconsistent with property values, and renting becomes only a way to minimize loss while holding a property for more price appreciation.

The ability to accurately evaluate property becomes difficult as traditional valuation techniques break down. Inevitably, inexperienced buyers and out-of-area money enter the market. Investors not familiar with the street-by-street, neighborhood-by-neighborhood variables of an area become more prevalent, and an already difficult situation worsens.

In this win-lose scenario, many people lose money, and sellers are left with few or no options. After the market crashes and bottoms, speculators come back into the picture and the cycle repeats itself.

One lesson we can learn from Dallas and apply to other locales, which is different than Los Angeles or Las Vegas or Phoenix (another city undergoing a severe bust), involves the type of investor who enters the marketplace. This point is significant because, when I counsel sellers and review market data, properties must meet certain criteria.

Listings need to satisfy the interests of seasoned experts who know how to deal with the reality of a challenging environment. For example, a purely speculative investor who relies more on emotion than analysis may not know the history of a neighborhood, the strength of the rental market, or the repairs needed to transform a neglected home into a profitable investment.

Remember, distressed homes in a distressed marketplace require a radically different mindset than the outlook for a traditionally functioning real estate market.

The surest way to understand pricing in a distressed marketplace is to invest capital and take a risk position on a property — this is the unique perspective that a veteran real estate agent, broker or investor offers. Which means you must analyze the evaluation of properties on both a “market comparable” basis, and also as a long-term cash flow investment. In higher-priced and more speculative markets, a different approach applies.

The renewal of distressed properties is a win for everyone. By turning these homes around, and through our efforts on the ground, neighborhoods improve and price stability returns.

Equally important, recycling these distressed properties into quality retail homes (and clean rentals) aids those owners who are currently underwater on their mortgages. Experienced local investors who have a stake in the long-term economic viability of a community are completely aligned with the interests of homeowners.

That’s a recipe for success.

Charles E. “Chas” Carrier is a principal of We Buy Ugly Houses Dallas, a HomeVestors of America Inc. franchisee.

Nanoparticles Could Lead to Stronger Drugs, Fewer Side Effects for Cancer Patients

A biotech company called Cerulean says its nanoparticle-delivered cancer drugs are better at attacking tumors.

Thursday, August 30, 2012

One result of the side effects of cancer treatments is that patients often can’t tolerate or survive a combination of different drugs at the same time—which can limit a doctor’s ability to knock out the disease. The head of a Boston-area biotech called Cerulean Pharma thinks the solution is nanoparticle-delivered drugs, which have fewer and less severe side effects. They could make it easier for doctors to mount a multipronged attack on tumors and kill the cells before they can develop a resistance to any one compound.

Cancer cells can develop resistance to individual drugs very quickly, says Oliver Fetzer, CEO of Cerulean. And he points to recent studies showing that different cells within the same tumor can have different genetic mutations. In some cases, that means that a drug that kills cancer cells in one part of a tumor may not work in other parts. This tumor diversity suggests that it would be best to hit cancer cells with multiple drugs at once to make it extremely difficult for the tumor to develop resistance to all therapies.

Nanoparticles could help achieve this goal. The nanoparticles developed by Cerulean are too big to get out of blood vessels and into healthy tissue, but they are the right size to get into tumors because the blood vessels that grow around cancer tissue have pores or gaps that aren’t found in healthy tissue. “These nanoparticles find their way into the tumor through the leaky [blood vessels], so they can’t really escape out of your normal bloodstream in the healthy tissue,” says Fetzer. Once inside the tumor tissue, cancer cells take them in.

Cerulean’s nanoparticle acts like time-release packaging—instead of dumping all the cancer drug into the tumor at one time, the nanoparticle slowly breaks down and releases the drug bit by bit. A feature of Cerulean’s technology is that the nanoparticle and the drug are connected by a chemical bond. While drugs in other nanoparticles used in delivery are held by polymer meshes or inside a fatty capsule, drugs in Cerulean’s nanoparticles are tethered by a chemical link. The drug is released as the chemical bond is broken, a process partly controlled by an unknown enzyme in the body. That rate of release can be tuned using different linkers, says Fetzer.

Data from early clinical trials of Cerulean’s lead compound—a nanoparticle containing a drug called Camptothecin that is too toxic to be administered on its own—suggests it is well-tolerated. Patients in the trial experienced fewer and milder side effects than do patients given available drugs.

Another player in the nanoparticle-delivery space, BIND Biosciences, adds a layer of specificity to its delivery by affixing targeting molecules to the outside of its nanoparticles (see “Fine-tuning Nanotech to Target Cancer“). The targeting molecules recognize proteins on the outside of cancer cells and so help bring the nanopharmaceutical to its desired location.

Fetzer says that while there may be applications where the targeting is helpful, his company does not think it is necessary. “When we look at the data we’ve generated with untargeted particles, we haven’t seen the need to add another layer of complexity.”

The company expects to have results from its human trials of its lead compound in treating lung cancers by the end of the 2012. It recently began testing the effectiveness of the same compound in ovarian cancer patients. To begin to explore the possibility of combining nanoparticle-based cancer drugs with other therapies, Cerulean is also enrolling patients with kidney cancer in a phase I trial that will combine the company’s lead compound with bevacizumab, a commercially available cancer drug used in a variety of cancers